Inferra AIResearch Tools

Inferra AI / Company / EW

Edwards Lifesciences

EW · Health Care

Last earnings Jul 23, 2026  ·  Next earnings Nov 4, 2026

AI analysis

Q2 2025 · reported Jul 24, 2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

No extracted figures held

The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.

Guidance · company-stated

Direction: Raised

Revenue$5.9 billion

“Outlook Edwards is increasing its full-year total company sales growth guidance to 9% to 10% with sales of $5.9 billion to $6.1 billion.”

Revenue

“In addition, the company is increasing its underlying growth rate guidance for TAVR to 6% to 7%, driven by strong performance, and its sales guidance range for TAVR to $4.3 billion to $4.5 billion.”

Classified from the release's primary full-year outlook statement.

Next earningsNov 4, 2026Verified from the company’s own announcement

Capital allocation

Total debt was approximately $600 million.

government and agency securities $ 241.9 $ ( 0.1 ) $ 8.0 $ ( 0.3 ) $ 249.9 $ ( 0.4 ) Asset-backed securities 13.2 ( 0.1 ) 20.8 ( 0.4 ) 34.0 ( 0.5 ) Corporate debt securities 586.6 ( 0.5 ) 15.3 ( 0.1 ) 601.9 ( 0.6 ) $ 841.7 $ ( 0.7 ) $ 44.1 $ ( 0.8 ) $ 885.8 $ ( 1.5 ) December 31, 2025 Less than 12 Months 12 Months or Greater Total Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses U.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Edwards Lifesciences Q2 2025 results

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

Direction: Raised

Revenue: “Outlook Edwards is increasing its full-year total company sales growth guidance to 9% to 10% with sales of $5.9 billion to $6.1 billion.”

Revenue: “In addition, the company is increasing its underlying growth rate guidance for TAVR to 6% to 7%, driven by strong performance, and its sales guidance range for TAVR to $4.3 billion to $4.5 billion.”

Revenue — Raised (“raising”)
“Based on our better-than-expected first half performance and the many catalysts across our portfolio, we are confident in our full-year outlook and are raising our sales and EPS guidance, said Bernard Zovighian, CEO.”

Revenue — Raised (“increasing”)
“Outlook Edwards is increasing its full-year total company sales growth guidance to 9% to 10% with sales of $5.9 billion to $6.1 billion.”

Revenue — Raised (“increasing”)
“In addition, the company is increasing its underlying growth rate guidance for TAVR to 6% to 7%, driven by strong performance, and its sales guidance range for TAVR to $4.3 billion to $4.5 billion.”

Revenue — Reiterated (“remains unchanged”)
“Sales guidance for the company s TMTT and Surgical product groups remains unchanged.”

Classified from the release's primary full-year outlook statement.

Capital allocation

Total debt was approximately $600 million.

SEC original ↗Edwards Lifesciences — Earnings release (8-K exhibit)EX-99Jul 24, 2025

government and agency securities $ 241.9 $ ( 0.1 ) $ 8.0 $ ( 0.3 ) $ 249.9 $ ( 0.4 ) Asset-backed securities 13.2 ( 0.1 ) 20.8 ( 0.4 ) 34.0 ( 0.5 ) Corporate debt securities 586.6 ( 0.5 ) 15.3 ( 0.1 ) 601.9 ( 0.6 ) $ 841.7 $ ( 0.7 ) $ 44.1 $ ( 0.8 ) $ 885.8 $ ( 1.5 ) December 31, 2025 Less than 12 Months 12 Months or Greater Total Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses U.

SEC original ↗Edwards Lifesciences — 10-Q Quarterly report10-QAug 4, 2026

government and agency securities $ $ $ 11.2 $ ( 0.4 ) $ 11.2 $ ( 0.4 ) Asset-backed securities 5.1 ( 0.1 ) 24.3 ( 0.5 ) 29.4 ( 0.6 ) Corporate debt securities 76.7 ( 0.1 ) 34.3 ( 0.3 ) 111.0 ( 0.4 ) $ 81.8 $ ( 0.2 ) $ 69.8 $ ( 1.2 ) $ 151.6 $ ( 1.4 ) The Company reviews its investments in debt securities to determine if there has been an other-than-temporary decline in fair value.

SEC original ↗Edwards Lifesciences — 10-Q Quarterly report10-QAug 4, 2026

The unrealized losses on the debt securities were largely due to changes in interest rates, not credit quality, and as of June 30, 2026, the Company did not intend to sell the securities, and it was not more likely than not that it would be required to sell the securities before recovery of the unrealized losses, and, therefore, the unrealized losses are considered temporary.

SEC original ↗Edwards Lifesciences — 10-Q Quarterly report10-QAug 4, 2026

Financial instruments of the Company consist of cash deposits, accounts and other receivables, investments, accounts payable, certain accrued liabilities, and borrowings under a revolving credit agreement.

SEC original ↗Edwards Lifesciences — 10-Q Quarterly report10-QAug 4, 2026

government and agency securities 214.1 214.1 Commercial paper 460.7 460.7 Equity investments in unconsolidated entities 28.8 28.8 Investments held for deferred compensation plans 174.2 174.2 Derivatives 51.4 51.4 $ 1,432.8 $ 2,455.3 $ $ 3,888.1 Liabilities Derivatives $ $ 6.3 $ $ 6.3 Contingent consideration liabilities 9.9 9.9 Other 6.1 6.1 $ $ 6.3 $ 16.0 $ 22.3 December 31, 2025 Assets Cash equivalents $ 1,366.7 $ 1,020.0 $ $ 2,386.7 Available-for-sale investments: Corporate debt securities 346.9 346.9 Asset-backed securities 35.0 35.0 U.

SEC original ↗Edwards Lifesciences — 10-Q Quarterly report10-QAug 4, 2026

Strategy & priorities

, the company continues to focus on the value of its differentiated technology and increasing therapy adoption, especially in areas where many patients go without care.

SEC original ↗Edwards Lifesciences — Earnings release (8-K exhibit)EX-99Jul 24, 2025

Edwards continues to see great demand for the therapy and continues to develop important evidence to support expansion globally.

SEC original ↗Edwards Lifesciences — Earnings release (8-K exhibit)EX-99Jul 24, 2025

This year-over-year change was driven by additional manufacturing expenses related to the expansion of new therapies as well as foreign exchange.

SEC original ↗Edwards Lifesciences — Earnings release (8-K exhibit)EX-99Jul 24, 2025

This increase in spending and decrease in R D as a percentage of sales reflects Edwards' strategic prioritization of investments in its expanding structural heart portfolio.

SEC original ↗Edwards Lifesciences — Earnings release (8-K exhibit)EX-99Jul 24, 2025

Zovighian and statements regarding the third quarter and fiscal year 2025 financial guidance, our expected growth and accelerating growth due to, among other things, asymptomatic TAVR approval global adoption of, and differentiated features of, our devices progress of the EVOQUE commercial launch feedback on SAPIEN M3 our ability to deliver significant value to patients, healthcare ecosystem and shareholders expansion of evidence, approvals, clinical trial outcomes and impacts patient outcomes the highlights in the Guidance and Outlook section and the information in the Outlook section.

SEC original ↗Edwards Lifesciences — Earnings release (8-K exhibit)EX-99Jul 24, 2025

Risks & headwinds

Edwards guidance reflects the Company s current estimates of the impact from tariffs that are in effect or have been announced as of the time of this press release and assumes such tariffs remain in place for the remainder of 2025.

SEC original ↗Edwards Lifesciences — Earnings release (8-K exhibit)EX-99Jul 24, 2025

Any modification to such tariffs, or any new tariffs, could have a material impact on the Company s future financial results and guidance.

SEC original ↗Edwards Lifesciences — Earnings release (8-K exhibit)EX-99Jul 24, 2025

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements.

SEC original ↗Edwards Lifesciences — Earnings release (8-K exhibit)EX-99Jul 24, 2025

Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include risk and uncertainties associated with the risks detailed in the company's filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2024, and its other filings with the SEC.

SEC original ↗Edwards Lifesciences — Earnings release (8-K exhibit)EX-99Jul 24, 2025

Adjusted earnings per share from continuing operations is a non-GAAP item computed on a diluted basis and in this press release also excludes certain litigation expenses, amortization of intangible assets, loss on impairment, and separation costs.

SEC original ↗Edwards Lifesciences — Earnings release (8-K exhibit)EX-99Jul 24, 2025

The Company uses the term adjusted to also exclude certain litigation expenses, amortization of intangible assets, loss on impairment, and separation costs.

SEC original ↗Edwards Lifesciences — Earnings release (8-K exhibit)EX-99Jul 24, 2025

Competitors

Competitors & peers

Named in the company’s own filings

Medtronic (MDT)“In TAVR, our primary competitors include Medtronic plc ( Medtronic ) and Abbott Laboratories ( Abbott ).”Abbott Laboratories (ABT)“In TAVR, our primary competitors include Medtronic plc ( Medtronic ) and Abbott Laboratories ( Abbott ).”
Documents

Filings

62 documents

Earnings releases

26 documents

Presentations

0 documents

No presentations for Edwards Lifesciences are held in this edition of the library.

Transcripts

0 documents

No transcripts for Edwards Lifesciences are held in this edition of the library.

Mentioned by

5 companies

Other tracked companies whose held documents mention Edwards Lifesciences by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.